Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy

S G Molhoek, J J Bax, L van Erven, M Bootsma, P Steendijk, E Lentjes, E Boersma, A van der Laarse, E E van der Wall, M J Schalij

Cardiac resynchronisation therapy (CRT) has recently been introduced to treat patients with drug refractory heart failure. Studies have demonstrated immediate haemodynamic improvement after CRT, followed by improvement in symptoms, quality of life, and exercise capacity. Although the majority of patients respond well to CRT, in 20% of patients symptoms do not improve. The main problem is the lack of objective parameters to measure the effect of CRT.

Natriuretic peptides are now used in studies involving patients with heart failure. The value of these markers to objectively assess response to CRT was evaluated in this study.

METHODS

Based on traditional selection criteria (New York Heart Association (NYHA) functional class III–IV, left ventricular ejection fraction (LVEF) < 35%, QRS duration > 120 ms, and left bundle branch block configuration), 30 consecutive patients, of whom 23 were men (mean (SD) age 65 (12) years), underwent biventricular pacemaker implantation; 13 had ischaemic and 17 had idiopathic dilated cardiomyopathy. Medication consisted of diuretics, angiotensin converting enzyme inhibitors, spironolactone, β blockers, and/or amiodarone, and remained unchanged during the entire study.

The day before implantation, echocardiography was performed in combination with tissue Doppler imaging (TDI) (to assess left ventricular dyssynchrony). Clinical evaluation included assessment of NYHA class, ECG (QRS duration, morphology), quality of life, and six minute walking distance. Blood samples were obtained for the evaluation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). The evaluation was repeated seven months after CRT.

Peripheral venous blood was collected in sampling tubes containing EDTA as the anticoagulant. Plasma was separated and stored at −80°C until the measurement of N terminal ANP and N terminal BNP concentrations by immunoassay (N terminal-ANP ELISA (1–98) code number BI-20892 and N terminal-BNP ELISA (1–76), code number BI-20852; Biomedica, Vienna, Austria).

Data were expressed as mean (SD). Comparison of data was performed using the Student t test for paired and unpaired data when appropriate. Since BNP and ANP are not normally distributed, we applied a log transformation. Paired Student’s t tests were applied to evaluate differences in the log transformed BNP and ANP concentrations before and after CRT. Analysis of variance was applied to evaluate BNP and ANP patterns between responders and non-responders.

Univariate analysis for categorical variables was performed using the χ² test with Yates’ correction. Simultaneous comparison of > 2 mean values was performed by using one way analysis of variance (ANOVA) with Bonferroni correction. For all tests a probability value of p < 0.05 was considered significant.

RESULTS

The QRS duration was 176 (22) ms. The mean NYHA class was 3.1 (0.3), the quality of life score was 39 (18), and the six minute walking distance was 259 (130) m.

LVEF was 21 (9%) (range 12–33%). Five patients had 4+, five had 3+, and seven had 2+ mitral regurgitation. TDI demonstrated a delay between peak systolic velocity in the septum and the lateral wall of 72 (30) ms, illustrating LV dyssynchrony.

Plasma concentrations of ANP and BNP were 10 522 (8091) pmol/l and 1242 (955) pmol/l, respectively.

Based on the improvement in NYHA class at seven months, patients were divided into responders (n = 20) and non-responders (n = 10). Baseline characteristics were not different between the two groups (table 1). All echocardiographic results at baseline were comparable, except for the left ventricular dyssynchrony: responders exhibited a larger delay between the septum and lateral wall, as compared to non-responders (table 1). Mean plasma concentrations of peptides were not different between the two groups (table 1).

The improvement in symptoms was accompanied by an improvement in quality of life score (from 39 (15) to 28 (15), p < 0.01), six minute walking distance (from 264 (106) m to 385 (122) m, p < 0.01), and LVEF (from 22 (7%) to 31 (9%), p < 0.05). Mitral regurgitation grade 3+ or 4+ was present in six patients and improved by ≥ 1 grade in five. TDI showed significantly different parameters between responders and non-responders (table 1).

Univariate analysis for categorical variables was performed using the χ² test with Yates’ correction. Simultaneous comparison of > 2 mean values was performed by using one way analysis of variance (ANOVA) with Bonferroni correction. For all tests a probability value of p < 0.05 was considered significant.

Peripheral venous blood was collected in sampling tubes containing EDTA as the anticoagulant. Plasma was separated and stored at −80°C until the measurement of N terminal ANP and N terminal BNP concentrations by immunoassay (N terminal-ANP ELISA (1–98) code number BI-20892 and N terminal-BNP ELISA (1–76), code number BI-20852; Biomedica, Vienna, Austria).

Data were expressed as mean (SD). Comparison of data was performed using the Student t test for paired and unpaired data when appropriate. Since BNP and ANP are not normally distributed, we applied a log transformation. Paired Student’s t tests were applied to evaluate differences in the log transformed BNP and ANP concentrations before and after CRT. Analysis of variance was applied to evaluate BNP and ANP patterns between responders and non-responders.

Univariate analysis for categorical variables was performed using the χ² test with Yates’ correction. Simultaneous comparison of > 2 mean values was performed by using one way analysis of variance (ANOVA) with Bonferroni correction. For all tests a probability value of p < 0.05 was considered significant.

RESULTS

The QRS duration was 176 (22) ms. The mean NYHA class was 3.1 (0.3), the quality of life score was 39 (18), and the six minute walking distance was 259 (130) m.

LVEF was 21 (9%) (range 12–33%). Five patients had 4+, five had 3+, and seven had 2+ mitral regurgitation. TDI demonstrated a delay between peak systolic velocity in the septum and the lateral wall of 72 (30) ms, illustrating LV dyssynchrony.

Plasma concentrations of ANP and BNP were 10 522 (8091) pmol/l and 1242 (955) pmol/l, respectively.

Based on the improvement in NYHA class at seven months, patients were divided into responders (n = 20) and non-responders (n = 10). Baseline characteristics were not different between the two groups (table 1). All echocardiographic results at baseline were comparable, except for the left ventricular dyssynchrony: responders exhibited a larger delay between the septum and lateral wall, as compared to non-responders (table 1). Mean plasma concentrations of peptides were not different between the two groups (table 1).

The improvement in symptoms was accompanied by an improvement in quality of life score (from 39 (15) to 28 (15), p < 0.01), six minute walking distance (from 264 (106) m to 385 (122) m, p < 0.01), and LVEF (from 22 (7%) to 31 (9%), p < 0.05). Mitral regurgitation grade 3+ or 4+ was present in six patients and improved by ≥ 1 grade in five. TDI showed

Abbreviations: ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CRT, cardiac resynchronisation therapy; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; TDI, tissue Doppler imaging
an improvement of dysynchrony and the delay in peak systolic velocities between the septum and lateral wall improved from 90 (20) ms to 44 (28) ms (p < 0.01). Plasma concentrations of ANP and BNP decreased significantly (fig 1).

Fifteen of 20 (75%) of responders showed more than a 10% reduction in ANP or BNP plasma concentrations.

No improvement was seen in quality of life scores, exercise capacity, or LVEF; mitral regurgitation grade 3+ or 4+ was present in four patients and none improved at follow up. TDI did not show improvement in left ventricular dyssynchrony. In the non-responders, plasma concentrations of ANP and BNP did not improve (fig 1).

Nine of 10 (90%) of non-responders did not show a reduction in ANP or BNP plasma concentrations of more than 10%.

**DISCUSSION**

The majority of patients with end stage heart failure benefit from CRT, although objective assessment of response is difficult.1 2 Studies have used improvement in NYHA class, which is a rather subjective parameter, as a marker of benefit. More objective parameters, such as quality of life score, six minute walking distance, and LVEF have also been used.

In search of additional parameters to address severity of heart failure, natriuretic peptides have been used.3 In the current study patients with an improvement in clinical status showed a reduction in ANP and BNP plasma concentrations after CRT, suggesting the usefulness of natriuretic peptides as an objective and quantitative marker to evaluate response to CRT.

Natriuretic peptides may be even more useful as prognostic markers than as diagnostic markers. Omland and colleagues have shown that raised plasma concentrations of natriuretic peptides, in particular BNP, were predictive of mortality.4 The potential prognostic value of natriuretic peptides in patients treated with CRT therapy needs further study.

**Table 1** Baseline characteristics of responders and non-responders

<table>
<thead>
<tr>
<th></th>
<th>Responders (n = 20)</th>
<th>Non-responders (n = 10)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>15/5</td>
<td>8/2</td>
<td>NS</td>
</tr>
<tr>
<td>Age (years)</td>
<td>67 (9)</td>
<td>60 (16)</td>
<td>NS</td>
</tr>
<tr>
<td>Aetiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ischaemic v non-ischaemic</td>
<td>8/12</td>
<td>5/5</td>
<td>NS</td>
</tr>
<tr>
<td>QRS (ms)</td>
<td>178 (21)</td>
<td>172 (25)</td>
<td>NS</td>
</tr>
<tr>
<td>NYHA class</td>
<td>3.15 (0.4)</td>
<td>3.0 (0.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Qol score</td>
<td>38 (15)</td>
<td>40 (24)</td>
<td>NS</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>26 (106)</td>
<td>258 (192)</td>
<td>NS</td>
</tr>
<tr>
<td>MR grade 3–4+</td>
<td>6 (30%)</td>
<td>4 (40%)</td>
<td>NS</td>
</tr>
<tr>
<td>S-L dyssync (ms)</td>
<td>90 (20)</td>
<td>37 (11)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>N terminal ANP (pmol/l)</td>
<td>11184 (7339)</td>
<td>9198 (9711)</td>
<td>NS</td>
</tr>
<tr>
<td>N terminal BNP (pmol/l)</td>
<td>1368 (761)</td>
<td>989 (1269)</td>
<td>NS</td>
</tr>
</tbody>
</table>

ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NS, not significant; NYHA, New York Heart Association; Qol, quality of life; S-L dyssync, difference between septal and lateral peak systolic velocities, indicating dyssynchrony within the left ventricle; 6 min WT, 6 minute walk test.
Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy

S G Molhoek, J J Bax, L van Erven, M Bootsma, P Steendijk, E Lentjes, E Boersma, A van der Laarse, E E van der Wall and M J Schalij

Heart 2004 90: 97-98
doi: 10.1136/heart.90.1.97

Updated information and services can be found at:
http://heart.bmj.com/content/90/1/97

These include:

References
This article cites 4 articles, 0 of which you can access for free at:
http://heart.bmj.com/content/90/1/97#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Clinical diagnostic tests (4779)
- Dilated cardiomyopathy (292)
- Echocardiography (2127)
- Heart failure (565)
- Mitral valve disease (229)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/